New Leaf boosts financing round to $30 million

New Leaf Symbiotics, a Creve Coeur firm using bacterial treatments to boost crop yields, has added $6 million to a venture-capital financing round it announced in July.

The Series C round, originally $24 million, has grown to $30 million, New Leaf said Thursday. Chicago-based S2G Ventures joined the group of lead investors, which also included Monsanto Growth Ventures and Otter Capital of Palo Alto, Calif. Lewis & Clark Ventures of Clayton is among the other investors.

Sanjeev Krishnan, an S2G managing director, said in a statement that New Leaf “has created a product pipeline that can move the needle in ag biologicals.”

The company will use the money to commercialize its bacterial treatments for soybeans, corn, wheat, peanuts and other crops. New Leaf also is tripling the size of its research and pilot production facility in Creve Coeur, where it employs more than 30 people.

View article, here.